Potent Vesicular Stomatitis Virus-based Avian Influenza Vaccines Provide Long-term Sterilizing Immunity Against Heterologous Challenge

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2010 Feb 26

PMID 20181720

Citations 24

Authors

Jennifer A Schwartz

Linda Buonocore

Amorsolo L Suguitan Jr

Alex Silaghi

Darwyn Kobasa

Gary Kobinger

Heinz Feldmann

Kanta Subbarao

John K Rose

Affiliations

Soon will be listed here.

Abstract

The emergence in 1997 and continuance today of a highly lethal H5N1 avian influenza virus (AIV) causing human disease has raised concern about an impending pandemic and the need for a vaccine to prepare for such an occurrence. We previously generated an efficacious vesicular stomatitis virus (VSV)-based AIV vaccine expressing H5 hemagglutinin (HA) from the fifth genomic position of VSV (J. A. Schwartz et al., Virology 366:166-173, 2007). Here we have generated and characterized VSV-based vaccines that express the A/Hong Kong/156/1997 (clade 0) H5 HA from the first position of the VSV genome. These vectors induce broadly cross-neutralizing antibodies against homologous and heterologous H5N1 viruses of different clades in mice. The vaccines provide complete protection against morbidity and mortality after heterologous challenge with clade 0 and clade 1 strains in animals even 1 year after vaccination. Postchallenge pulmonary virus loads show that these vectors provide sterilizing immunity. Therefore, VSV-based AIV vaccines are potent, broadly cross-protective pandemic vaccine candidates.

Citing Articles

A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades.

Furuyama W, Reynolds P, Haddock E, Meade-White K, Quynh Le M, Kawaoka Y NPJ Vaccines. 2020; 5(1):4.

PMID: 31934358 PMC: 6954110. DOI: 10.1038/s41541-019-0155-z.

Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".

Melzer M, Lopez-Martinez A, Altomonte J Biomedicines. 2017; 5(1).

PMID: 28536351 PMC: 5423493. DOI: 10.3390/biomedicines5010008.

Viral vector-based influenza vaccines.

de Vries R, Rimmelzwaan G Hum Vaccin Immunother. 2016; 12(11):2881-2901.

PMID: 27455345 PMC: 5137548. DOI: 10.1080/21645515.2016.1210729.

Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir.

Ren H, Wang G, Wang S, Chen H, Chen Z, Hu H MAbs. 2016; 8(6):1156-66.

PMID: 27167234 PMC: 4968093. DOI: 10.1080/19420862.2016.1183083.

Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.

Ryder A, Nachbagauer R, Buonocore L, Palese P, Krammer F, Rose J J Virol. 2015; 90(5):2544-50.

PMID: 26676789 PMC: 4810685. DOI: 10.1128/JVI.02598-15.

References

Cooper D, Wright K, Calderon P, Guo M, Nasar F, Johnson J . Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol. 2007; 82(1):207-19. PMC: 2224363. DOI: 10.1128/JVI.01515-07. View

Baras B, Stittelaar K, Simon J, Thoolen R, Mossman S, Pistoor F . Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One. 2008; 3(1):e1401. PMC: 2151135. DOI: 10.1371/journal.pone.0001401. View

Haglund K, Leiner I, Kerksiek K, Buonocore L, Pamer E, Rose J . Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins. J Virol. 2002; 76(15):7506-17. PMC: 136360. DOI: 10.1128/jvi.76.15.7506-7517.2002. View

Suguitan Jr A, McAuliffe J, Mills K, Jin H, Duke G, Lu B . Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 2006; 3(9):e360. PMC: 1564176. DOI: 10.1371/journal.pmed.0030360. View

Kapadia S, Rose J, Lamirande E, Vogel L, Subbarao K, Roberts A . Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology. 2005; 340(2):174-82. PMC: 7111745. DOI: 10.1016/j.virol.2005.06.016. View

Gillim-Ross L, Subbarao K . Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev. 2006; 19(4):614-36. PMC: 1592697. DOI: 10.1128/CMR.00005-06. View

Ehrlich H, Muller M, Oh H, Tambyah P, Joukhadar C, Montomoli E . A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med. 2008; 358(24):2573-84. DOI: 10.1056/NEJMoa073121. View

Rose N, Roberts A, Buonocore L, Rose J . Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol. 2000; 74(23):10903-10. PMC: 113169. DOI: 10.1128/jvi.74.23.10903-10910.2000. View

Ramsburg E, Publicover J, Buonocore L, Poholek A, Robek M, Palin A . A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J Virol. 2005; 79(24):15043-53. PMC: 1316007. DOI: 10.1128/JVI.79.24.15043-15053.2005. View

10.

Geisbert T, Daddario-DiCaprio K, Lewis M, Geisbert J, Grolla A, Leung A . Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008; 4(11):e1000225. PMC: 2582959. DOI: 10.1371/journal.ppat.1000225. View

11.

Treanor J, Campbell J, Zangwill K, Rowe T, Wolff M . Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006; 354(13):1343-51. DOI: 10.1056/NEJMoa055778. View

12.

Geisbert T, Daddario-DiCaprio K, Geisbert J, Reed D, Feldmann F, Grolla A . Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008; 26(52):6894-900. PMC: 3398796. DOI: 10.1016/j.vaccine.2008.09.082. View

13.

Roberts A, Kretzschmar E, Perkins A, Forman J, Price R, Buonocore L . Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol. 1998; 72(6):4704-11. PMC: 109996. DOI: 10.1128/JVI.72.6.4704-4711.1998. View

14.

Fouchier R, Munster V, Wallensten A, Bestebroer T, Herfst S, Smith D . Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol. 2005; 79(5):2814-22. PMC: 548452. DOI: 10.1128/JVI.79.5.2814-2822.2005. View

15.

Fuerst T, Niles E, Studier F, Moss B . Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A. 1986; 83(21):8122-6. PMC: 386879. DOI: 10.1073/pnas.83.21.8122. View

16.

Leroux-Roels I, Van der Wielen M, Kafeja F, Vandermeulen C, Lazarus R, Snape M . Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. Vaccine. 2009; 27(49):6918-25. DOI: 10.1016/j.vaccine.2009.08.110. View

17.

Hickman D, Hossain M, Song H, Araya Y, Solorzano A, Perez D . An avian live attenuated master backbone for potential use in epidemic and pandemic influenza vaccines. J Gen Virol. 2008; 89(Pt 11):2682-2690. PMC: 2886961. DOI: 10.1099/vir.0.2008/004143-0. View

18.

Schwartz J, Buonocore L, Roberts A, Suguitan Jr A, Kobasa D, Kobinger G . Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology. 2007; 366(1):166-73. PMC: 3356997. DOI: 10.1016/j.virol.2007.04.021. View

19.

Russell C, Jones T, Barr I, Cox N, Garten R, Gregory V . Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine. 2009; 26 Suppl 4:D31-4. DOI: 10.1016/j.vaccine.2008.07.078. View

20.

Govorkova E, Webby R, Humberd J, Seiler J, Webster R . Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis. 2006; 194(2):159-67. DOI: 10.1086/505225. View